Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment.

Radoslaw Laufer, Bryan Forrest, Sze-Wan Li, Yong Liu, Peter Sampson, Louise Edwards, Yunhui Lang, Donald E Awrey, Guodong Mao, Olga Plotnikova, Genie Leung, Richard Hodgson, Irina Beletskaya, Jacqueline M Mason, Xunyi Luo, Xin Wei, Yi Yao, Miklos Feher, Fuqiang Ban, Reza Kiarash, Erin Green, Tak W Mak, Guohua Pan, Henry W Pauls, None, The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents. Journal of Medicinal Chemistry. ,vol. 56, pp. 6069- 6087 ,(2013) , 10.1021/JM400380M

W. C. Zimmerman, R. L. Erikson, Polo-like kinase 3 is required for entry into S phase. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 104, pp. 1847- 1852 ,(2007) , 10.1073/PNAS.0610856104

Yan Degenhardt, Joel Greshock, Sylvie Laquerre, Aidan G. Gilmartin, Junping Jing, Mark Richter, Xiping Zhang, Maureen Bleam, Wendy Halsey, Ashley Hughes, Christopher Moy, Nancy Liu-Sullivan, Scott Powers, Kurtis Bachman, Jeffrey Jackson, Barbara Weber, Richard Wooster, Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability Molecular Cancer Therapeutics. ,vol. 9, pp. 2079- 2089 ,(2010) , 10.1158/1535-7163.MCT-10-0095

Hartmut Döhner, Michael Lübbert, Walter Fiedler, Loic Fouillard, Alf Haaland, Joseph M. Brandwein, Stephane Lepretre, Oumedaly Reman, Pascal Turlure, Oliver G. Ottmann, Carsten Müller-Tidow, Alwin Krämer, Emmanuel Raffoux, Konstanze Döhner, Richard F. Schlenk, Florian Voss, Tillmann Taube, Holger Fritsch, Johan Maertens, Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy Blood. ,vol. 124, pp. 1426- 1433 ,(2014) , 10.1182/BLOOD-2014-03-560557

David Olmos, Douglas Barker, Rohini Sharma, Andre T. Brunetto, Timothy A. Yap, Anne B. Taegtmeyer, Jorge Barriuso, Hanine Medani, Yan Y. Degenhardt, Alicia J. Allred, Deborah A. Smith, Sharon C. Murray, Thomas A. Lampkin, Mohammed M. Dar, Richard Wilson, Johann S. de Bono, Sarah P. Blagden, Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies Clinical Cancer Research. ,vol. 17, pp. 3420- 3430 ,(2011) , 10.1158/1078-0432.CCR-10-2946

J.W. Hudson, A. Kozarova, P. Cheung, J.C. Macmillan, C.J. Swallow, J.C. Cross, J.W. Dennis, Late mitotic failure in mice lacking Sak, a polo-like kinase. Current Biology. ,vol. 11, pp. 441- 446 ,(2001) , 10.1016/S0960-9822(01)00117-8

X. S. Liu, B. Song, J. Tang, W. Liu, S. Kuang, X. Liu, Plk1 phosphorylates Sgt1 at the kinetochores to promote timely kinetochore-microtubule attachment. Molecular and Cellular Biology. ,vol. 32, pp. 4053- 4067 ,(2012) , 10.1128/MCB.00516-12

Wolfgang Reindl, Juping Yuan, Andrea Krämer, Klaus Strebhardt, Thorsten Berg, Inhibition of polo-like kinase 1 by blocking Polo-box domain-dependent protein-protein interactions Chemistry & Biology. ,vol. 15, pp. 459- 466 ,(2008) , 10.1016/J.CHEMBIOL.2008.03.013

Timothy J. Lansing, Randy T. McConnell, Derek R. Duckett, Glenn M. Spehar, Victoria B. Knick, Daniel F. Hassler, Nobuhiro Noro, Masaaki Furuta, Kyle A. Emmitte, Tona M. Gilmer, Robert A. Mook, Mui Cheung, In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1 Molecular Cancer Therapeutics. ,vol. 6, pp. 450- 459 ,(2007) , 10.1158/1535-7163.MCT-06-0543

X. Shawn Liu, Bing Song, Bennett D. Elzey, Timothy L. Ratliff, Stephen F. Konieczny, Liang Cheng, Nihal Ahmad, Xiaoqi Liu, Polo-like Kinase 1 Facilitates Loss of Pten Tumor Suppressor-induced Prostate Cancer Formation Journal of Biological Chemistry. ,vol. 286, pp. 35795- 35800 ,(2011) , 10.1074/JBC.C111.269050